“We pay sofosbuvir” – a drug for the treatment of hepatitis C – “37,000 euros as an admission price. Several studies show that at a cost of 40,000 euros it is convenient to eradicate the disease”. This was stated to Adnkronos Salute by the director general of the Italian Medicines Agency (Aifa), Luca Pani, in Rome on the sidelines of a congress on corruption in healthcare, organized by the Catholic University. “We – adds Pani – have negotiated a discount of 17%. As we promised – concludes Pani – we closed at the much lower average price in Europe”.
November 6, 2014 – PharmaKronos
Related news: Hepatitis C: the drug is there, the money not yet (THE PRINT)
Hepatitis C, there will be an ad hoc fund. Lorenzin: "New therapies for everyone" (CORRIERE DELLA SERA / HEALTH)
